title: [Cytomegalovirus in liver transplantation: incidence and groups at risk].
abstract: Cytomegalovirus (CMV) belongs to the family of Herpes viridae and has become the single most important viral pathogen in clinical transplantation. This is an endemic and ubiquitous virus. After transplantation it is necessary to distinguish CMV infection (positive seroconversion and/or isolation of the virus in the blood, urine, sputum or tissues in the absence of clinical symptoms) from CMV disease, which is a clinical expression of viremia in association with a documented CMV infection. The overall incidence of CMV infection in transplant recipients is about 50% and the incidence of CMV disease ranges from 15 to 25% whatever the transplanted organ. In this study (52 liver transplantations in 48 patients), 12 patients had CMV infection and 10 patients developed CMV disease (24%). The onset of CMV disease was 33 +/- 7 days after transplantation. Cytomegalovirus hepatitis was observed 7 times, CMV pneumonia once and 2 CMV infections characterized by oscillating fever in association with a hematological syndrome. 8 patients were treated with intravenous gancyclovir (DHPG, 9-[1,3-dihydroxy-2-propoxymethyl]-guanine) for 15 days and 2 patients by reduction of their immunosuppressive therapy only. There were significantly more (p < 0.05) opportunistic infections and/or bacteremia in patients with CMV disease. The association of CMV IgG negative recipients and CMV IgG positive donors appeared to be a significant factor (p < 0.05) for CMV disease. The number of transfusions, the level of immunosuppression and the absence of prophylaxis did not influence the incidence of CMV disease. Despite prolonged hospitalization and increased morbidity, there were no deaths in patients who developed CMV disease, which is good evidence of the efficacy of gancyclovir.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de chirurgie et pédiatrie, Hôpital cantonal universitaire, Genève.
authors.forename: V
authors.initials: V
authors.lastname: Schiffer
authors.forename: G
authors.initials: G
authors.lastname: Mentha
authors.forename: E
authors.initials: E
authors.lastname: Giostra
authors.forename: D
authors.initials: D
authors.lastname: Belli
authors.forename: C
authors.initials: C
authors.lastname: Le Coultre
authors.forename: A
authors.initials: A
authors.lastname: Rohner
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000382:microbiology*; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents; D007223:Infant; D016031:Liver Transplantation; D008875:Middle Aged; D009894:Opportunistic Infections / Q000382:microbiology*; D011183:Postoperative Complications / Q000382:microbiology*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D007166:Immunosuppressive Agents; D015774:Ganciclovir
vernacular_title: Le cytomégalovirus chez les transplantés du foie: incidence et groupes à risques.